Norwegian version of this page

Kidney Transplantation

The research group carries out epidemiological and clinical outcome studies in kidney transplantation, pancreas transplantation and islet transplantation.

About the group

The research group carries out epidemiological and clinical outcome studies in kidney transplantation, pancreas transplantation and islet transplantation.

Data from the Norwegian Renal Registry (which is updated yearly) together with data from a local biobank are generated, together with RCTs and observational studies.

The studies focus on immunotherapy, pharmacokinetics, pharmacotherapeutic modelling and metabolism, in particular post-transplant bone disease metabolism and also post-transplant diabetes (PTDM).


  • SIMPLIFY study: Simplification of the plasma clearance of iohexol
  • Patiromer PK study: Effect of patiromer on pharmacokinetics of immunosuppressive drugs in renal transplant recipients
  • Hypomagnesemia as a risk factor for development of posttransplant diabetes mellitus (PhD project Rasmus Kirkeskov Carlsen)
  • The microbiome and gut metabolism of mycophenolate acid
  • Covid-19 vaccine study among kidney transplant recipients
  • EVITA (Epstein-Barr virus infection monitoring in renal transplant recipients)
  • BONTRAX – 10 years follow-up of bisphosphonate treatment in kidney transplant recipients
  • Home Based Monitoring – patient centric sampling for analyses of tacrolimus, creatinine and hemoglobin
  • Post-transplant diabetes mellitus
  • Kidney rejection and immunity
  • Individualization of immunosuppression, also with home based blood sampling (MitraTip®)
  • Biomarkers of outcomes after transplantation
  • Measured GFR by iohexol plasma clearance vs. estimated glomerular filtration rate
  • Evaluation and follow-up of kidney donors (ALDON Study)
  • Long-term effects and safety with human pancreas transplantation.

In relation to these topics altogether 65 peer-reviewed papers were published in international journals in 2022.

Our biobank was expanded, and we have established valid measures for long-term outcome after transplantation (e.g., GFR, pharmacological and metabolic measures, inflammation parameters, etc.).

We have received an EU grant as partner in a twinning project of the Horizon program: Diabetes, Obesity & the Kidney (DOKI).

The research group received a large grant from KLINBEFORSK to start a randomized, blinded and placebo-controlled intervention study on the SGLT2 inhibitor dapagliflozin in kidney transplant recipients. The purpose of the study is to see whether SGLT2 inhibition can prolong the survival time for transplanted kidney grafts.



  • Section of Endocrinology
  • Section of Transplant surgery
  • Department of Pathology
  • Department of Immunology
  • Department of Pediatrics


  • University of Oslo, AHUS - Renal research Group
  • University of Tromsø- Renal research Group
  • University of Bergen- Department of nephrology
  • University of Stavanger, Department of nephrology
  • School of Pharmacy, UiO
  • Department of Nutrition, UiO


  • Laboratory for Applied Pharmacokinetics and Bioinformatics, University of Southern California
  • Professor Esteban Porini, La Laguna University, Tenerife, Spain
  • Professor Manfred Hecking, Medical Universtiy of Vienna, Austria
  • CHU Limoges, Department of Pharmacology and Toxicology, Limoges, France
  • Andreas Paasch, Caltec, Basel
  • Professor Filip Knop, Center for Diabetes Research, Gentofte Hospital, Copenhagen
  • Professor Bo Feldt-Rasmussen, Department of Nephrology, Rigshospitalet, Copenhagen


  • Heldal TF, Åsberg A, Ueland T, Reisæter AV, Pischke SE, Mollnes TE, Aukrust P, Hartmann A, Heldal K, Jenssen T. Inflammation in the early phase after kidney transplantation is associated with increased long-term all-cause mortality. Am J Transplant 2022; 22(8): 2016-2027.
  • Tsarpali V, Midtvedt K, Lønning K, Bernklev T, Åsberg A, Fawad H, von der Lippe N, Reisæter AV, Røysland K, Heldal K. A comorbidity index predicts survival in older recipients of deceased donor kidney transplantation; a national prospective study. Transplant Direct 2022; 8(4): e1307.
  • Kvitne KE, Robertsen I, Skovlund E, Christensen H, Krogstad V, Wegler C, Angeles PC, Wollmann BM, Hole K, Johnson LK, Sandbu R, Artursson P, Karlsson C, Andersson S, Andersson TB, Hjelmesæth J, Jansson-Löfmark R, Åsberg A. Short- and long-term effects of body weight loss following calorie restriction and gastric bypass on CYP3A-activity - a non-randomized three-armed contro 32.
  • Haugen AJ, Hallan S, Langberg NE, Dahle DO, Pihlstrøm H, Birkeland KI, Reisæter AV, Midtvedt K, Hartmann A, Holdaas H, Mjøen G. Increased risk of ischaemic heart disease after kidney donation. Nephrol Dial Transplant. 2022; 37(5): 928-936. lled trial. Clin Transl Sci 2022; 15(1): 221-233.
  • Dahle DO, Skauby M, Langberg CW, Brabrand K, Wessel N, Midtvedt K. Renal Cell Carcinoma and Kidney Transplantation: A Narrative Review. Transplantation. 2022; 106(1): e52-e63.
Published Aug. 14, 2018 10:36 AM - Last modified Sep. 11, 2023 11:07 AM


Group leader


Detailed list of participants

Page visits: 3202